Monday, 5 August 2013

Leaky gut and autism: the story so far

Gut or intestinal hyperpermeability a.k.a leaky gut has been a point of some contention when it comes to a complicated set of conditions like the autisms.

Describing the process and mechanism of disruption to the quite delicate barrier which separates our intestinal contents from the wider environment and functions of the body, mention leaky gut to some people and you'll get some pretty peculiar looks. Allied perhaps unfairly to the realm of complementary and alternative medicine (CAM), leaky gut in some circles has not received great press in its attempts to offer an explanation for lots of different (chronic) conditions including autism.
Rumplestiltskin @ Wikipedia 

With autism specifically in mind, leaky gut seemingly encompasses all the most controversial elements about the condition: (i) involvement of the gastrointestinal (GI) tract, (ii) discussions about its possible link with food and diet (more to come on that), and (iii) other variables including who and from where the message about leaky gut originates from.

That and portraying autism as potentially being more than the sum of just the brain as being involved in the presentation of its behavioural characteristics and you have all the required elements in place to push leaky gut into the nether regions of autism research discussions. 

In this mega-post I'm going to ask that you put any prejudice aside for a short while as I intend to have a close look at the [limited] peer-reviewed and almost peer-reviewed evidence mentioning leaky gut and autism. I'll say now that I'm not going to offer some shining recommendation for leaky gut as being a core part of all cases of autism or even that it is a primary part of presentation; the available evidence does not point to that. Instead I'm going to put forward a view that leaky gut might, just might, be a part of some of the complexity of autism, some autism, and where present might offer some interesting leads into underlying pathology and/or intervention.

What is leaky gut?
OK, I should have probably mentioned this before but the name leaky gut is a bit of a misnomer when it comes to describing what might be going on in our deepest, darkest recesses. Everyone has some degree of leaky gut or gut permeability; if not, how would we be able to absorb nutrients from food for example. It's perhaps more pertinent to talk about excess gut permeability or gut hyperpermeability as describing the scenario more accurately.

The basic tenet of leaky gut, sorry gut hyperpermeability, is that the normally 'fairly porous to a certain degree' gut barrier is for whatever reason more permeable and porous than it should be and as a result various 'chemicals' (yep the misuse of that word again) and other material including bacteria and friends, are able to make a journey into the gut membrane and perhaps beyond.

OK so what's the problem with that I hear you ask? Well, the gut barrier is there for a reason and part of that reason is so that our immune system for example, does not get to meet certain biochemicals and bacteria in certain places of the body and do what it is designed to do, mount an immune response against them as part of its protection duties. Think bacterial translocation* - gut bacteria appearing in places other than the gut - as one example. Actually the immune system is only part of the proposed issue here which anyone who has an interest in autism research history and the opioid-excess theory** will know and the suggestion that dietary peptides are able to traverse this barrier and in some shape or form activate opiate receptors. Speculation at least; but if you read my training post on coeliac (celiac) disease, you'll know that gluten peptides can move into at least one part of the gut barrier for whatever reason.

Leaky gut and medicine
Taking aspirin affects the permeability of the gut. No really, it's true as per papers like this one***. Drinking alcohol affects gut permeability too****. What these and other papers demonstrate is that gut permeability is a dynamic process which is very much affected by environmental conditions such as what medicines we take and what we eat and drink. Would you believe me if I told you that taking something like melatonin might also affect gut permeability too (at least in rats)? Albeit in the opposite direction from aspirin and alcohol.

It's also been known for quite a few years that various conditions manifest issues with gut permeability as per the example of the inflammatory bowel diseases (IBDs)***** (open-access). Indeed, various other conditions with an autoimmune element to them have been a real point of discussion with gut hyperpermeability in mind, as per the chatter about type 1 diabetes****** for example.

I'm going to come on to autism shortly, but various other suggestions have been made linking leaky gut to disease and ill-health. One of them - Chronic Fatigue Syndrome (CFS) - has been talked about a few times with this permeability issue in mind on other blogs I'm linked to (see here). Indeed the name Dr Michael Maes carries quite an impressive array of articles on leaky gut and bacterial translocation in relation to all manner of conditions and indeed, some clues as to what intervention might also be able to do*******.

Leaky gut and autism
To save me typing the whole thing out again, I've talked about leaky gut and autism previously on another site (see here). The gist of that article detailed the main papers making up the autism and leaky gut scene to date: D'Eufemia and colleagues******** and their initial intestinal permeability results, Robertson and colleagues********* saying not so fast albeit including participants who were on dietary intervention and de Magistris and colleagues********** (see full-text here) who agreeing with D'Eufemia also suggested that gut permeability might be influenced by the use of a gluten- and casein-free (GFCF) diet so potentially also answering the whys of the Robertson findings.

There is also the conference presentation by Paul Patterson and colleagues (see here) on leaky gut in his offspring mouse model of maternal immune activation (which itself has seen some research action lately) but let's wait until that sees the peer-reviewed light of day. Oh and we have the next installment from de Magistris and colleagues (see here) which will have a post of its own soon [hint: leaky gut remains present in some people on the autism spectrum].

As per my introducing leaky gut with autoimmunity in mind, you might also be able to see how gut permeability issues could potentially be present in cases of autism which also include autoimmune comorbidity for example. So IBDs for example (see here) or coeliac disease (see here) or even type 1 diabetes (see here) might all elevate risk of abnormal gut permeability if present.

Based on this accumulated work alongside other speculations as a function of things like immune reactivity to gluten peptides for example (see here) there is a favourable base to gut hyperpermeability being a feature of autism in anything up to a third of cases. Indeed, outside of the direct measurement of gut permeability, other papers have also mentioned leaky gut in their text; for example as an explanation for those antibodies to Sutterella bacteria found in some cases of autism (see here).

More to see
I've not specifically mentioned about how one goes about assessing gut permeability because that in itself offers a number of potential routes worthy of a post of its own (lactulose:mannitol, PEG, etc.). Nor have I talked about where permeability is greatest in the gut in relation to autism or the issue of what type of permeability might exist (transcellular vs. paracellular). And as for other potential players in gut permeability such as [general] zonulin (see here) and the continuing saga of whether dietary intervention might 'affect' permeability*********** (no medical advice given or intended) or indeed other interventions .... we wait to see what future research offers about these factors specifically with autism in mind.

So after all that, still think leaky gut in autism is a load of old tosh?

----------

* Berg RD. Bacterial translocation from the gastrointestinal tract. Adv Exp Med Biol. 1999;473:11-30.

** Shattock P. & Whiteley P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets. 2002 Apr;6(2):175-83.

*** Lambert GP. et al. Effect of aspirin dose on gastrointestinal permeability. Int J Sports Med. 2012 Jun;33(6):421-5. doi: 10.1055/s-0032-1301892.

**** Worthington BS. et al. Effect of daily ethanol ingestion on intestinal permeability to macromolecules. Am J Dig Dis. 1978; 23: 23-32.

***** Gerova VA. et al. Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test. World J Gastroenterol. 2011 May 7; 17(17): 2211–2215.

****** Vaarala O. Leaking gut in type 1 diabetes. Curr Opin Gastroenterol. 2008 Nov;24(6):701-6. doi: 10.1097/MOG.0b013e32830e6d98.

******* Maes M. & Leunis JC. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett. 2008 Dec;29(6):902-10.

******** D'Eufemia P. et al. Abnormal intestinal permeability in children with autism. Acta Paediatr. 1996 Sep;85(9):1076-9.

********* Robertson MA. et al. Intestinal permeability and glucagon-like peptide-2 in children with autism: a controlled pilot study. J Autism Dev Disord. 2008 Jul;38(6):1066-71. doi: 10.1007/s10803-007-0482-1.

********** de Magistris L. et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010 Oct;51(4):418-24. doi: 10.1097/MPG.0b013e3181dcc4a5.

*********** Sildorf SM. et al. Remission without insulin therapy on gluten-free diet in a 6-year old boy with type 1 diabetes mellitus. BMJ Case Rep. 2012 Jun 21;2012. pii: bcr0220125878. doi: 10.1136/bcr.02.2012.5878.

----------

ResearchBlogging.org de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, Carteni M, De Rosa M, Francavilla R, Riegler G, Militerni R, & Bravaccio C (2010). Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. Journal of pediatric gastroenterology and nutrition, 51 (4), 418-24 PMID: 20683204

Saturday, 3 August 2013

Allergy and brain autoantibodies in autism?

The Saudi-Egyptian autism research tag-team of Gehan Mostafa and Laila Al-Ayadhi have been quiet of late on this blog. Regular readers will remember them from such studies as IL-17A elevated in cases of autism (see here) and S100B protein elevated in autism (see here).

My name.. JR Hartley @ Wikipedia
One of their latest offerings* looking at brain autoantibodies builds on some earlier work of theirs suggesting that alongside lower levels of vitamin D (the sunshine vitamin), higher levels of anti-MAG (anti-myelin associated glycoprotein) autoantibodies were also found. I'll freely admit to being more than a little confused by their assessment of anti-MAG autoantibodies and how it fitted into the whole vitamin D findings but, hey-ho.

In their latest paper they suggest that anti-MAG brain autoantibodies and anti-MAP (anti-myelin basic protein) autoantibodies might actually have more of a correlation / connection to cases of autism also presenting "with allergic manifestations".

It does seem like there is a bit of fishing expedition going on here as per some even older findings from the tag-team in relation to (or rather not) hyperserotonemia as per this article** (open-access).

That's not to say that these autoantibodies might not be important to cases of autism as per papers like this one*** from the late Reed Warren and colleagues (he of the C4B null allele and sIgA) acknowledging not albeit for everyone. Indeed an even more recent paper of their points towards as much**** (open-access). The recent description of MAR autism also widens the whole autoantibody area above and beyond just the person concerned.

I'm just not sure however that fishing for associations is necessarily the right way to go about looking at the relationships present in these findings. (Sorry)

----------

* Mostafa GA, Al-Ayadhi LY. The possible relationship between allergic manifestations and elevated serum levels of brain specific auto-antibodies in autistic children. J Neuroimmunol. 2013 May 29. pii: S0165-5728(13)00087-8.

** Mostafa GA, Al-Ayadhi LY. A lack of association between hyperserotonemia and the increased frequency of serum anti-myelin basic protein auto-antibodies in autistic children. J Neuroinflammation. 2011 Jun 22;8:71. doi: 10.1186/1742-2094-8-71.

*** Singh VK. et al. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immun. 1993 Mar;7(1):97-103.

**** Al-Ayadhi LY. & Mostafa GA. Elevated serum levels of macrophage-derived chemokine and thymus and activation-regulated chemokine in autistic children. J Neuroinflammation. 2013 Jun 19;10(1):72.

----------

ResearchBlogging.org Mostafa GA, & Al-Ayadhi LY (2013). The possible relationship between allergic manifestations and elevated serum levels of brain specific auto-antibodies in autistic children. Journal of neuroimmunology PMID: 23726766

Saturday, 27 July 2013

Coeliac Disease - a training post

You're probably wondering why, with all the reams of autism research being produced every day, that I'm dedicating a post to describing coeliac (celiac) disease on this blog? Well, the answer is simple; I've talked about coeliac disease (CD) quite a bit in relation to autism (here) and schizophrenia (here) and other conditions (here) but I'm mindful that not everyone actually knows what it is or what we think we currently know about it.
Gluten @ Wikipedia  

So in future occasions when I talk about CD in relation to some wonderful new study, I've got this training post as mine and yours go-to reference for the condition.

If you want the long and complicated story of CD, there are plenty of peer-reviewed papers which I could suggest you read such as this one from Kagnoff* (open-access) or this one from Meresse and colleagues** (open-access). There are lots of other papers on the topic too but if you want the Mr Men version, read on.

Gluten protein and peptides
CD is a condition governed by genes and environment in pretty equal measure. I suppose it all starts with foods containing the protein gluten. Actually gluten is a bit of a catch-all word because it combines two types of protein: gliadin and glutenin. Gluten is a protein which consists of long chains of amino acids. When ingested, various enzymes go to work on chopping up the protein into those nutritious rich amino acids that our bodies so rely on. But digestion does not just see the gluten protein immediately exploded into its constituent amino acids but rather breaking the protein down chunk by chuck to form small chains of amino acids called peptides along with way.

If you're a follower of autism research and in particular the whole gluten- and casein-free dietary intervention thing, you'll probably have heard about peptides as per the opioid-excess theory*** (open-access) put forward as one explanation for why diet might 'work' for some on the autism spectrum. It's still a little bit contentious but that's perhaps a topic for another day.

Anyhow, gluten is not an easy protein to digest as per the presence of certain amino acids such as glutamine and proline in that protein chain, the chemistry of which don't like being degraded easily. So what you potentially get are quite a few peptides swimming around our gastrointestinal (GI) tract which are not completely degraded into their simplest building block form, the amino acids.

Gut access
These gluten, sorry gliadin, peptides however don't just stay in the gut; some of them are also able to gain access to a part of the gut barrier called the lamina propria. Once there, something rather interesting seems to happen in cases of CD. The peptides come across something called tissue transglutaminase (tTG) something else which has cropped up on this blog with autism in mind (see here). The clue is in the name about tTG (also called TG2) and what it can do: -ase means it's an enzyme and the glutaminase bit means that it does things to the amino acid glutamine. The specific duty it does is a process called deamidation which basically involves the conversion of glutamine to glutamic acid (otherwise known as glutamate). Without getting too much into the chemistry of this process, the newly deamidated gliadin peptide is now 'super-charged' (neutral into negatively charged amino acids) in terms of its attraction (binding affinity) to molecules of the almighty MHC - major histocompatability complex or HLA in humans (see here).

DQ2 and DQ8
OK, so a quick recap. Gluten protein digested into gluten peptides. Said peptides meet and greet tTG and funny things start to happen to them.

Next in the process chain of CD is how these newly enhanced peptides from an immunogenicity point of view are met by the cells of the MHC and the sparks that fly as a result. Just in case you didn't click on my link talking about the MHC, it's all about how things are presented to the immune system and in particular, the tricky task of making sure that 'self' is not confused with 'other' by the immune system.

The genetics of CD represent the important part of this next stage of proceedings as per the HLA-DQ2 and DQ8 heterodimers; in effect the genes of CD. It's all about inheritance patterns as to whether or not a person will have two or one or no copies of these genes as a consequence of genetic zygosity.

HLA DQ2 or DQ8 molecules are part of the antigen presenting cells (APCs). Those newly enhanced gluten peptides fit nicely into the 'pocket' of the DQ2 and/or DQ8 molecules and once there activate T cells or more specifically a Th1 CD4+ response**** (open-access) focused on gliadin. This eventually leads to the release of cytokines such as IFN-γ (see here also) and TNF which then go on to damage the gut mucosa as a function of their important role in the process of inflammation.

This is quite a simplistic overview of the main processes involved in CD. As per the discussions on the Kagnoff and Meresse papers, there are still quite a few unknowns about the whole process of CD. There's also the relatively newer work coming into the science of CD such as a role for zonulin (see this post) and its 'gatekeeper' role in relation to the gut barrier and things like the wheat amylase trypsin inhibitors (thanks Jad).

The gluten-free diet
As you'll probably already know, management of CD is primarily via the use of a gluten-free diet. The theory being that if there is still no starting material (gluten) to form those peptides, even though the genetics may be there, there is nothing or only little material for tTG or the DQ2/DQ8 molecules to go to work on.

That being said, you'll probably also see a few other potential areas where other interventions might also be developed***** (open-access). So how about helping to degrade those gluten peptides? What about stopping those peptides from meeting tTG? Blocking DQ8 and DQ2 molecules? Or even reducing the release or blocking the effects of those cytokines? And the good things is that research is underway in some of these areas.

Testing for coeliac disease
Just before you go it might also be worthwhile mentioning about how one goes about testing for CD in light of some confusion in this area over the years. It's worth pointing out that an accurate diagnosis of CD relies on more than one test (see here) covering serology, gut biopsy and on occasion, genetic testing. One of the more recent professional consensus statements on testing can be seen here****** (open-access).

And finally.... please don't take my word for it, do some research yourself.

---------

* Kagnoff MF. Celiac disease: pathogenesis of a model immunogenetic disease. J Clin Invest. 2007 Jan;117(1):41-9.

** Meresse B. et al. Celiac disease: from oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesis. Mucosal Immunol. 2009 Jan;2(1):8-23. doi: 10.1038/mi.2008.75.

*** Whiteley P. et al. How Could a Gluten- and Casein-Free Diet Ameliorate Symptoms Associated with Autism Spectrum Conditions? Autism Insights 2010:2 39-53.

**** Nilsen EM. et al. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 1999; 115: 551-563.

***** Bakshi A. et al. Emerging Therapeutic Options for Celiac Disease: Potential Alternatives to a Gluten-Free Diet. Gastroenterol Hepatol (N Y). 2012 Sep;8(9):582-588.

****** Husby S. et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease. JPGN. 2012; 54: 136-160.

----------

ResearchBlogging.org Meresse B, Ripoche J, Heyman M, & Cerf-Bensussan N (2009). Celiac disease: from oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesis. Mucosal immunology, 2 (1), 8-23 PMID: 19079330

Monday, 22 July 2013

Epilepsy in autism revisited

I've said it before and I'll say it again, a diagnosis of autism or autism spectrum disorder is seemingly protective of nothing when it comes to comorbidity. Indeed, in these days of common ground and overlap (think ESSENCE) one of the more positive changes in thinking about autism is the move away from viewing the condition as some sort of homogenous, stand-alone diagnosis ripe for over-arching generalised theories. It's not.

Stealing a kiss @ Wikipedia  
Of that growing list of comorbidity which can and does sometimes follow autism, one condition or set of conditions in particular, has the ability to severely impact on the health and wellbeing of a person, in some unfortunate cases leading to the most severe outcomes: epilepsy.

I've covered the topic of epilepsy and seizure disorders previously on this blog (see here). The main conclusion from that post was that epilepsy represents one of the more common comorbidities which can present alongside autism and that there is no positive side to being diagnosed with epilepsy in terms of how it can affect quality of life and how it is, in some cases, linked to early mortality.

With these facts in mind, I was therefore interested to read the paper by Emma Viscidi and colleagues* (open-access) which looked at a number of issues around the autism-epilepsy link in terms of the prevalence of epilepsy and some of the factors which might influence the start and presentation of epilepsy in cases of autism.

The paper is open-access so there's no real need for me to get the fine-toothed comb out on it. I will however summarise some key points:

  • Based on participant data from four separate initiatives - AGRE, Simons Simplex collection, Autism Consortium, NSCH 2007 - authors collated data on nearly 6000 mainly young people diagnosed with an autism spectrum condition.
  • There were some differences among the various datasets in terms of how the diagnostic coding of autism was arrived at which needs to be kept in mind with this paper, but on the whole most diagnoses were confirmed by gold-standard assessment tools.
  • In terms of the presence of epilepsy, these were "based on parent report in all of the samples" without independent, professional verification of the diagnosis.
  • Several other facets of presentation were [variably] collected / ascertained from the available datasets including things like cognitive ability, history of developmental regression (see here) and the severity of autism presentation (at least at the time of initial presentation to the various initiatives).
  • Results: well, bearing in mind some variability between the datasets and various demographic slants such as participants being predominantly male and white, the frequency of reported epilepsy occurring in cases of autism ranged from 2.9% - 6.7% and the prevalence (based on the NSCH 2007 data) was 12.5%.
  • When stratifying the data across age groups (6 and below, 7-9, 10-12, 13 and above years) it appeared that older chronological age was associated with an increased frequency of reports of epilepsy; from the NSCH data, upwards of 25% of 13 year olds and older with autism were reported to present with epilepsy.
  • Similarly other recorded factors also seemed to be linked to the appearance of epilepsy including: the presence of developmental regression, those with poorer language skills, lower cognitive ability, etc.
  • The authors conclude that "epilepsy is a common co-morbid condition in individuals with ASD" and that "low IQ is the best clinical predictor of epilepsy in children with ASD".

As I've mentioned, there are some pretty big holes in this research; not least the lack of independent verification when it comes to the presence of epilepsy or not. Actually, I'm going to rephrase that last sentence to say that this is not a 'hole' in the research but rather something that needs to be investigated further in light of my previous posts talking about parents actually being quite good at spotting clinical signs (see here) and other comorbidity (see here) when it comes to autism. A shocker I know.

That aside, there are several potentially important lessons which can be learned from this data, not least when it comes to 'predicting' who with autism, might eventually go on to develop epilepsy and hence where screening and clinical management for this particular comorbidity perhaps needs to be focused in these times of limited resources and austerity. The accompanying paper by Jedrzejczyk-Goral and colleagues** looking at what types of epilepsy might be more commonly associated with autism is also helpful.

The related issue of intellectual disability (ID) in cases of autism seemingly being a magnet for epilepsy is also worthy of greater follow-up. One wonders for example, whether this finding might overlap with the other data looking at things like genetics in relation to autism and how ID seems to shoulder the larger burden when it comes to CNV load for example (see here). Indeed, whether some of these CNVs or other point mutations (SNPs et al) might actually be more relevant to the onset of epilepsy than the presence of autism itself? And then what about that inborn error of the branched-chain amino acids work discussed not so long ago on this blog (see here) where epilepsy and autism was presented?

Finally(!) my thoughts also wander back to the recent chatter about ketogenic diets and autism (see here and here). I'm not for one minute giving anything like medical advice on this issue - don't mess with epilepsy or indeed, antiepileptics it seems (more to follow on this). I'm merely suggesting that when potentially knowing which children/young adults with autism are more likely to develop epilepsy, and given the increasing interest in managing certain types of epilepsy through the ketogenic approach, whether further controlled research might wish to have a closer look at whether there are important links (or not) between these areas.

To close, Radio 2 listeners here in the UK might recognise a version of this song... enjoy yourself (it's later than you think).

----------

* Viscidi EW. et al. Clinical Characteristics of Children with Autism Spectrum Disorder and Co-Occurring Epilepsy. PLoS ONE 2013;  8(7): e67797. doi:10.1371/journal.pone.0067797

** Jedrzejczyk-Goral B. et al. 1925 – The frequency of different types of seizures in children suffered from autism and epilepsy. European Psychiatry. 2013; 28: supplement (Abstracts of the 21th European Congress of Psychiatry).

----------

ResearchBlogging.org Viscidi EW (2013). Clinical Characteristics of Children with Autism Spectrum Disorder and Co-Occurring Epilepsy PLoS ONE DOI: 10.1371/journal.pone.0067797

Friday, 19 July 2013

Autism, gut problems and oxidative stress

I'm still a rank amateur when it comes to talking about many aspects of autism research. Mitochondrial dysfunction remains a particularly curious area of research to me as I might have mention previously, but other areas are equally as baffling.
Storm in a teacup @ Wikipedia 

Take for example oxidative stress and the various research done on this topic in connection to autism. Yes, I've touched upon some aspects of this wide, very wide, area of investigation in previous posts (see here and here) but still it's hard going for me and I don't mind admitting it.

I therefore approach the paper by Phillip Gorrindo and colleagues* (open-access) with some degree of trepidation, and their suggestion that the presence of gastrointestinal (GI) issues appearing alongside cases of autism might very well be implicated in the whole oxidative stress area.

Some of you might remember the name Phillip Gorrindo and the excellent study** he was involved with suggesting that when mums and dads of children with autism talk about GI or bowel problems presenting in their children, professionals may do well to listen to them rather than fobbing them off as merely being 'non-experts'. By saying this I'm implying that parents are partners when it comes to identifying such issues as they are in other areas.

In this latest paper - which again has some media attention attached to it - we are told of three reasons why the authors chose to look at autism, GI issues and oxidative stress based on (i) the gut and brain possessing a "likely shared susceptibility to insults", (ii) that old mitochondrial ticket (see here again), and (iii) the links already made between autism and oxidative stress. The inclusion of the GI bit stems, I assume, from the previous focus of the author's work and quite a large volume of other research looking at GI issues and oxidative stress (see here for example) outside of autism.

So:
  • Four groups of participants were included for study: ASD+GI issues (n=27), ASD alone (n=29), GI issues with no ASD (n=21) and an "unaffected" group (n=10). GI issues by the way, were defined as functional GI issues (constipation, reflux, IBS, abdominal pain).
  • Blood samples were provided by participants and plasma levels of F2-Isoprostanes were analysed blind via GC-MS (although not seemingly based on accurate mass). 
  • In addition, levels of plasma triglycerides were also measured explained due to the effects of blood lipids on F2-IsoPs.
  • Results: well, in all clinical groups, including the GI issues only group, mean levels of F2-IsoPs were above that seen in the unaffected control group.
  • Group levels of F2-IsoPs were significantly greater in the ASD+GI group compared with the ASD alone group (p=0.007), although the ASD+GI group and GI issues with no ASD group were not significantly different from one and another.
  • Plasma triglyceride measurements also suggested that compared to the unaffected control group, the other groups all presented with elevations.
  • As well as looking at just the biochemistry side of things, the authors also noted that when it came to looking at "social impairment", the ASD+GI group seemed to fare considerably worse than the other groups.
  • The authors conclude that: "individuals with co-occurring ASD and GID [gastrointestinal dysfunction] may exhibit clinical phenotypes that are sufficiently distinct from children with ASD".

There's little more for me to add to this entry that has not already been said. Yes, the participant numbers were on the small side and so one has to be careful not to make too many sweeping generalisations. That being said though this is not the first time that such biochemical findings have been noted in cases of autism**. Quite by coincidence, I also stumbled across this recent paper by Ghezzo and colleagues*** (open-access) and this paper by Signorini and colleagues**** (open-access) both of which mention the isoprostanes (the Signorini paper with Rett syndrome in mind too). Isoprostanes with autism or autistic behaviours in mind seem to be rising in importance and with it their link to oxidative stress (see here).

I personally would have liked to have seen other markers linked to oxidative stress and its defences also measured and reported in this study. That very big elephant in the room that is glutathione is perhaps an important marker for future work in this area. I happened also to stumble across this article by Sido and colleagues***** (open-access) which talked about glutathione and inflammatory bowel disease (IBD) which might very possibly be relevant to those cases of autism where functional GI issues are part and parcel of something altogether more complicated (see here). Indeed the focus in the Sido article on cysteine brings us back to another important, if slightly under-rated, autism research avenue: sulphate (or sulfate if you wish).

To close, some music from Sonic Youth: 100% and some background on Joe.

----------

* Gorrindo P. et al. Enrichment of Elevated Plasma F2t-Isoprostane Levels in Individuals with Autism Who Are Stratified by Presence of Gastrointestinal Dysfunction. PLoS ONE 8(7):2013;  e68444. doi:10.1371/journal.pone.0068444

** Ming X. et al. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids. 2005 Nov;73(5):379-84.

*** Ghezzo A. et al. Oxidative Stress and Erythrocyte Membrane Alterations in Children with Autism: Correlation with Clinical Features. PLoS One. 2013 Jun 19;8(6):e66418.

**** Signorini C. et al. Isoprostanes and 4-Hydroxy-2-nonenal: Markers or Mediators of Disease? Focus on Rett Syndrome as a Model of Autism Spectrum Disorder. Oxid Med Cell Longev. 2013;2013:343824.

**** Sido B. et al. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut. 1998 Apr;42(4):485-92.

----------

ResearchBlogging.org Gorrindo P (2013). Enrichment of Elevated Plasma F2t-Isoprostane Levels in Individuals with Autism Who Are Stratified by Presence of Gastrointestinal Dysfunction PLoS ONE DOI: 10.1371/journal.pone.0068444

Tuesday, 16 July 2013

The gut microbiota and ME/CFS

Continuing a common theme of gut bacteria on this blog, most recently with autism in mind, my attention today turns to a paper by Frémont and colleagues* looking at the gut microbiota in cases of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS).

Cross my palm @ Wikipedia 
This is not the first time that those trillions of bacterial masters of ours have cropped up on this blog with CFS/ME in mind as per my recent post on yuck factor 10 and the fecal microbiota transplant (FMT) with CFS/ME in mind (see here).

Frémont et al utilised the most commonly used tool of the bacteriologists trade, high-throughput 16S rRNA gene sequencing (see here for an overview** and here for some issues with the method), to classify bacteria derived from a lovely sample medium - stool samples - provided by 43 participants diagnosed with ME/CFS compared with 36 asymptomatic controls.

They reported a few interesting things.
  • Because samples were provided by both Belgian and Norwegian participants (both ME/CFS and control groups), the authors reported differences in the type of bacteria between the different country samples. I'm guessing that quite a lot of this variation has to do with environmental factors such as food preferences and the like as per what other studies have shown. We also know for example that what you eat can have a fairly important effect on what bacteria you have in your gut (see here).
  • "Norwegians showed higher percentages of specific Firmicutes populations" when looked at as a whole in comparison to the Belgian samples.
  • When comparing Norwegian CFS/ME participants with their fellow asymptomatic country-people "patients presented increased proportions of Lactonifactor and Alistipes, as well as a decrease in several Firmicutes populations". Readers who clicked on the link for more information about Alistipes might recognise the name carried by a particular species, A. finegoldii named in honour of one Sydney Finegold, a regular on the autism-gut bacteria research scene. 
  • "In Belgian subjects the patient/control separation was less pronounced, however some abnormalities observed in Norwegian patients were also found in Belgian patients". Not too much more to add there aside from the suggestion that searching for diagnosis-wide biomarkers for a heterogeneous condition like CFS/ME perhaps suffers from the same methodological ills as has been talked about with the autisms in mind (see here). That and the whole brain CFS/ME vs gut CFS/ME subgroup discussions that I've had on this blog. 

Appreciating that this was a relatively small scale study in terms of participant numbers, I'm intrigued by this study and its results. Heterogeneity in presentation and all the myriad of other factors which can and do affect gut bacteria are important interfering factors in any kind of research in this area. Indeed if one compares the gut microbiome with some of the other -omes such as the genome or epigenome, one starts to appreciate the similar issues involved in building up a picture of the underlying pathology behind a condition like CFS/ME in terms of no one gene or epigenetic factor probably working in isolation covering all cases. So it is probably true for the gut microbiome too.

That being said, unlike genes and to a lesser extent the epigenome, where differences are identified in the various phylum/class/order/family/genus/species of bacteria present potentially even in just subgroups of the condition, one would assume that some corrective intervention could be put in place which might, just might, affect the presentation of symptoms. Indeed the authors speculate on "treatments based on gut microbiota modulation (antibiotics, pre and probiotics supplementation)" which brings me to the paper by Groeger and colleagues**** and back to the original paper by Borody and colleagues***** and indeed outside of CFS/ME, that interesting case study on antibiotics and autism which I discussed recently (see here) [no medical advice is given or intended].

To close, Muscial Youth and a blast from the 80s past.

----------

* Frémont M. et al. High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients. Anaerobe. 2013 Jun 19. pii: S1075-9964(13)00092-9. doi: 10.1016/j.anaerobe.2013.06.002.

** Trichopoulou A. et al. Disparities in food habits across Europe. Proceedings of the Nutrition Society. 2002; 61, 553–558.

*** Větrovský T. & Baldrian P. The Variability of the 16S rRNA Gene in Bacterial Genomes and Its Consequences for Bacterial Community Analyses. PLoS ONE. 2013; 8(2): e57923. doi:10.1371/journal.pone.0057923

**** Groeger D. et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013 Jun 21;4(4).

***** Borody TJ. et al. The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherapy. Journal of the Australasian College of Nutritional and Environmental Medicine. 2012; 31: 3-8.

----------

ResearchBlogging.org Frémont M, Coomans D, Massart S, & De Meirleir K (2013). High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients. Anaerobe PMID: 23791918